GlaxoSmithKline Pharmaceuticals Limited — Others, 14-02-2025: Appointment

GlaxoSmithKline Pharmaceuticals Limited has announced a board meeting outcome, approving the un-audited standalone and consolidated financial results for the third quarter and nine months ending December 31, 2024. Additionally, the board has re-appointed Mr. Juby Chandy as Whole-time Director and Chief Financial Officer for a two-year term starting April 1, 2025. Mr. Chandy, an experienced finance leader with GSK since 2007, has held various key positions across regions. This leadership continuity may bolster confidence among investors, reflecting stability in financial management and strategic direction.